CN103989730A - Acalypha australis L. and fluoroquinolone antibacterial medicine containing compound medicine for livestock and poultry - Google Patents
Acalypha australis L. and fluoroquinolone antibacterial medicine containing compound medicine for livestock and poultry Download PDFInfo
- Publication number
- CN103989730A CN103989730A CN201410230436.XA CN201410230436A CN103989730A CN 103989730 A CN103989730 A CN 103989730A CN 201410230436 A CN201410230436 A CN 201410230436A CN 103989730 A CN103989730 A CN 103989730A
- Authority
- CN
- China
- Prior art keywords
- medicine
- poultry
- compound medicine
- livestock
- fluoroquinolone antibacterial
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
The invention relates to an Acalypha australis L. and fluoroquinolone antibacterial medicine containing compound medicine for livestock and poultry. The compound medicine comprises the following raw materials in parts by weight: 3-30 parts of fluoroquinolone antibacterial medicine and 5-200 parts of Acalypha australis L, wherein the fluoroquinolone antibacterial medicine is norfloxacin, ciprofloxacin or levofloxacin. Studies prove that after Acalypha australis L. is added to the antibacterial medicine, the resistance of bacteria to the antibacterial medicine can be reversed, thus improving the treatment effects of the antibacterial medicine. By preparing the compound medicine into powder, tablets, oral liquid or granules according to conventional methods and adding the compound medicine to feeds for livestock and poultry according to the additive amount of 0.1-7g of main medicine/kg of feed to feed the livestock and poultry, the medicine cost and the medicine residues can be substantially reduced, higher economic benefits can be created for farmers, and food safety is simultaneously ensured.
Description
Technical field
The invention belongs to poultry coli-infection treatment technology field, relate in particular to a kind of Guangxi precious jade medicine that contains containing the poultry compound medicine of pearl grass and fluoroquinolone antibacterial agent.
Background technology
Escherichia coli are common conditioned pathogens, also be normal a kind of disease of sending out, its multiple location severe infections such as chicken acute sepsis, peritonitis, hepatitis, pneumonia, enteritis of can formerly having carried out the coffin upon burial, also can secondary or mixed sending out in virosis, to aquaculture, causes huge economic loss.The beta-lactam lopps antibiotic such as amoxicillin, ampicillin, ceftiofur, ceftriaxone, amoxicillin/clavulanate, ampicillin/sulbactam are the conventional important drugs of this disease of control, along with cultivation scale intensive degree is more and more large, medication is more and more spread unchecked, its Resistant strain is more and more many, also more about the report of Drug Resistance of E. coli.Studies confirm that, one of main mechanism of drug resistance is to produce beta-lactamase, especially extended spectrumβ-lactamase (Extended-Spectrum β-lactamase, ESBLs), this enzyme can be more by force and is hydrolyzed rapidly beta-lactam nucleus, makes this class antibiotic lose antibacterial activity.ESBLs is the main enzyme type of beta-lactamase, and it is not only to cephalo three generations and aztreonam drug resistance, and aminoglycoside, quinolones and sulfonamides are to crossing drug resistant, only to carbapenems, a mould alkene class medicaments insensitive.Many documents have reported colibacillary multi-drug resistant and have produced ESBLs and have substantial connection, both at home and abroad to comparatively pay close attention to.The detection, extraction, enzyme that inventor has carried out food animal source pathogenic bacterium ESBLs recently presses down the researchs such as enzyme protection effect to antibiotic percent hydrolysis and sulbactam, Tazobactam Sodium and Chinese medicine; to part ESBLs, colibacillary drug sensitive test shows, its multidrug resistant rate is apparently higher than non-ESBLs bacterial strain.In addition, result also shows to produce ESBLs bacterial strain not only to the serious drug resistance of the third generation cephalosporins such as ceftiofur, and also to multiple antimicrobial drug drug resistance such as fluoroquinolones, aminoglycoside and sulfonamides, fosfomycin etc., is serious multidrug resistant.Inventor is separated to the escherichia coli that tolerate P-levels mycin produces fosA3 drug resistant gene in producing ESBLs bacterial strain, has more strengthened the drug resistance of antibacterial.Colibacillary drug resistance causes raiser's drug cost to increase, and treatment extends the course for the treatment of, and mortality of livestock increases, and to production, brings larger economic loss, and increases poultry drug residue risk.Therefore, in actual production, need a kind of to no matter whether, the escherichia coli of drug resistance can have the medicine of better therapeutical effect badly, and can shorten treatment course for the treatment of, reduce mortality rate, reducing economic loss and reduce drug residue, is that raiser creates higher economic benefit, also ensures that the mankind's is healthy and safe.
Summary of the invention
The technical problem to be solved in the present invention is to provide a kind of Guangxi precious jade medicine that contains containing the poultry compound medicine of pearl grass and fluoroquinolone antibacterial agent, it can kill antibacterial quickly, overcome antimicrobial drug treatment due to large, the residual height of weak curative effect, consumption and the high defect of cost that drug resistance problem causes, avoided that simple Chinese medicine sterilizing spectrum is narrow, slow problem sterilizes.
For solving above technical problem, the present invention by the following technical solutions: a kind of poultry compound medicine containing containing pearl grass and fluoroquinolone antibacterial agent, is comprised of the raw material of following weight portion: fluoroquinolone antibacterial agent 3-30 part, contains the careless 5-200 part of pearl.
Described fluoroquinolone antibacterial agent is norfloxacin, ciprofloxacin or levofloxacin.
Further, described compound medicine is comprised of the raw material of following weight portion: ciprofloxacin 3-20 part and containing pearl grass 40-180 part, or norfloxacin 3-25 part and containing pearl grass 30-190 part.
Described compound medicine is prepared into powder, tablet, oral liquid or granule.
The preparation method of described compound medicine is: will be containing broken mistake 60 mesh sieve of pearl grass meal, then mix with pulverous antimicrobial drug, be prepared into according to a conventional method powder, tablet, oral liquid or granule.
Containing pearl grass (Acalypha australis L.), have another name called Acalypha australis, Herba Acalyphae, people Herba Amaranthi tricoloris, belong to Euphorbiaceae Acalypha, draft is to suffruticose draft, and stem is very thin, thick below 3 millimeters, female flower bract is lobate, is lobate greatly, and length can reach 1 centimetre, do not divide, there is sawtooth at edge, and base portion is heart-shaped, female flower is kidney shape when open, when closed, is clam, wherein keeps fruit, therefore have the reputation of " Acalypha australis ", also therefore and easily identification.Originate in various places, Guangxi, be born on the ground waste or more moistening place, limit, village.Herb decocts that water is for oral administration can treat bacillary dysentery, diarrhoea etc.
The drug resistance problem existing for current poultry coli-infection, inventor utilizes Chinese medicine to contain pearl grass and antimicrobial drug composition compound medicine.Studies have shown that, in antimicrobial drug, add containing after pearl grass, can reverse the drug resistance of bacteria medicine, thereby improve the therapeutic effect of antimicrobial drug.According to a conventional method this compound medicine is made to powder, tablet, oral liquid or granule, according to the addition of 0.1-7g principal agent/kg feedstuff, add in animal and fowl fodder and feed, can significantly reduce drug cost and drug residue, for raiser creates higher economic benefit, also guaranteed food safety simultaneously.
The specific embodiment
One, the drug resistance inversion effect research to antimicrobial drug containing pearl grass
Antimicrobial drug itself has the colibacillary effect for the treatment of, but has stronger drug resistance owing to producing the escherichia coli of ESBLs drug resistant gene, causes antimicrobial drug not show good therapeutic effect in normal using dosage situation.
In order to verify containing the drug resistance inversion effect of pearl grass to antimicrobial drug, on 96 orifice plates, adopt microtest tube doubling dilution, first measured antimicrobial drug to the minimal inhibitory concentration of the e. coli strains of product ESBLs and fosA3 drug resistant gene and contained pearl grass to producing the subinhibitory concentration of ESBLs and fosA3 drug resistant gene e. coli strains, what then in culture medium, add subinhibitory concentration reuses containing pearl grass the minimal inhibitory concentration that microtest tube doubling dilution is cultivated mensuration antimicrobial drug; Utilize continuous passage method be added with same subinhibitory concentration containing the culture medium of pearl grass and same concentration antimicrobial drug in to producing the cultivation of going down to posterity of ESBLs and fosA3 drug resistant gene e. coli strains, until the antimicrobial drug minimal inhibitory concentration observing with go down to posterity before compare and diminish more than 4 times, can be judged as containing pearl grass antibacterial medical instrument is had to drug resistance inversion effect.Result of the test statistics is as shown in table 1:
Table 1 subinhibitory concentration (0.5g/mL) goes down to posterity and causes the variation (mg/mL) of producing ESBLs and fosA3 escherichia coli Western medicine MIC containing pearl grass.
As seen from the above table, antimicrobial drug all reduces more than 4 times the colibacillary minimal inhibitory concentration of drug resistance, can judge containing pearl grass and have drug resistance inversion effect to producing ESBLs and fosA3 drug resistant gene escherichia coli.
Two, the application example of compound medicine of the present invention
According to table 2, fill a prescription and following methods Preparation Example 1-embodiment 8: will be containing after broken mistake 60 mesh sieves of pearl grass meal, as basic material, again with pulverous antimicrobial drug by weight ratio put into blender and mix, according to a conventional method, compound medicine is prepared into formulation products.
The formula of table 2 embodiment 1-8 and preparation dosage form
| Numbering | Antimicrobial drug | Containing pearl grass | Dosage form |
| Embodiment 1 | Ciprofloxacin 3g | 120g | Tablet |
| Embodiment 2 | Ciprofloxacin 10g | 90g | Powder |
| Embodiment 3 | Ciprofloxacin 14g | 40g | Oral liquid |
| Embodiment 4 | Ciprofloxacin 20g | 180g | Granule |
| Embodiment 5 | Norfloxacin 13g | 190g | Tablet |
| Embodiment 6 | Norfloxacin 15g | 85g | Powder |
| Embodiment 7 | Norfloxacin 3g | 5g | Oral liquid |
| Embodiment 8 | Norfloxacin 25g | 30g | Granule |
Inventor obtains compound medicine product by above-described embodiment and has carried out following experiment:
1, the efficacy experiment of the compound medicine product of embodiment 1-4 gained to chicken escherichia coil disease
Clinical symptoms: Nanning chicken house, 26 age in days laying hens, there is fragmentary death in chicken group, cuts open the indivedual chickens of inspection and occur the pathological change of bag pericardium liver, typical bacillus coli feature.
Laboratory diagnosis: get pathologic liver and dye sheet, Gram’s staining, micro-Microscopic observation, the gram negative bacilli of red color visible; Tentatively be judged as bacillus coli.By escherichia coli, cultivate, biochemical test is differentiated, judges that chicken infects for bacillus coli, and pcr amplification, proves and produce the ESBLs drug resistant gene that has TEM type.
Test therapeutic regimen: morbidity chicken group is divided into 6 groups of administrations, use embodiment 1 according to the addition administration of 3.5g/kg feedstuff for first group, use embodiment 2 according to the addition administration of 1g/kg feedstuff for second group, use embodiment 3 according to the addition administration of 0.4g/kg feedstuff for the 3rd group, use embodiment 4 according to the addition administration of 1g/kg feedstuff for the 4th group; Use ciprofloxacin powder according to the addition administration of 0.1g/kg feedstuff for the 5th group, the 6th group with containing the thick powder of pearl grass according to the addition administration of 4g/kg feedstuff; Above six groups of therapeutic regimens all continue to use 5 days.
Effect feedback: after the chicken group medication of first group to the 4th group, sick chicken feed intake rises, and no longer occurs dead chicken, continues to use 3 days, and chicken group be almost recovered; The chicken group medication of the 5th group is after 2 days, and chicken group majority is still unhealthy, still has indivedual chicken deaths, continues to use 3 days, and chicken death phenomenon is not still effectively controlled; The chicken group medication of the 6th group is after 2 days, and chicken group does not have too large remarkable improvement, continues to use 3 days, and chicken death phenomenon is not still effectively controlled.Visible, the compound medicine curative effect containing containing pearl grass is better than folk prescription.
2, the efficacy experiment of the compound medicine product of embodiment 5-8 gained to the meat-type duck diarrhoea of 23 ages in days
Clinical symptoms: duck field, Liuzhou, 23 age in days meat-type duck, duck group draws watery stools, has obvious indigested feedstuff in feces.A duck group material feeding is not but long, and the serious duck appearance foot gradually of suffering from diarrhoea is individually soft slowly dead.
Cut open inspection pathological changes: the duck that dies of illness dehydration is more serious, indivedual ducks are still very large, duck liver enlargement, hyperemia, and adularescent film on the liver of part duck, air bag is muddy, and tentative diagnosis is escherichia coli or duck oromeningitis.
Test therapeutic regimen: morbidity duck group divides six groups of administrations, use embodiment 5 according to the addition administration of 3g/kg feedstuff for first group, use embodiment 6 according to the addition administration of 1.3g/kg feedstuff for second group, use embodiment 7 according to the addition administration of 0.5g/kg feedstuff for the 3rd group, use embodiment 8 according to the addition administration of 0.45g/kg feedstuff for the 4th group; Use norfloxacin powder according to the addition administration of 0.2g/kg feedstuff for the 5th group, the 6th group with containing the thick powder of pearl grass according to the addition administration of 4g/kg feedstuff; Above six groups of therapeutic regimens all continue to use 5 days.
Result of use feedback: first group to the 4th group medication is after 2 days, and sick duck is no longer drawn watery stools, feces is shaped, and no longer occurs dead duck, continues to use 3 days, and duck group be almost recovered; The 5th group of medication is after 2 days, and duck group DeGrain, much still draws watery stools, contain indigested feedstuff, continue to use 3 days some improvement a little, but not good thorough, rare watery stools still occurs, raiser cannot drug withdrawal, have to use the compound medicine of embodiment 6 gained instead, continue to use 2 days, just be almost recovered, re-use 1 day, feces all transfers to normally; The 6th group of medication is after 2 days, and duck does not have too large remarkable improvement, continues to use 3 days, and the duck phenomena of mortality are not still effectively controlled.Visible, the compound medicine containing containing pearl grass is better than folk prescription to the curative effect of duck diarrhoea.
Claims (4)
1. contain the poultry compound medicine containing pearl grass and fluoroquinolone antibacterial agent, it is characterized in that, by the raw material of following weight portion, formed: fluoroquinolone antibacterial agent 3-30 part, contains the careless 5-200 part of pearl.
2. the poultry compound medicine containing containing pearl grass and fluoroquinolone antibacterial agent according to claim 1, is characterized in that, described fluoroquinolone antibacterial agent is norfloxacin, ciprofloxacin or levofloxacin.
3. the poultry compound medicine containing containing pearl grass and fluoroquinolone antibacterial agent according to claim 1, it is characterized in that, described compound medicine is comprised of the raw material of following weight portion: ciprofloxacin 3-20 part and containing pearl grass 40-180 part, or norfloxacin 3-25 part and containing pearl grass 30-190 part.
4. the poultry compound medicine containing containing pearl grass and fluoroquinolone antibacterial agent according to claim 1, is characterized in that, described compound medicine is prepared into powder, tablet, oral liquid or granule.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410230436.XA CN103989730A (en) | 2014-05-28 | 2014-05-28 | Acalypha australis L. and fluoroquinolone antibacterial medicine containing compound medicine for livestock and poultry |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410230436.XA CN103989730A (en) | 2014-05-28 | 2014-05-28 | Acalypha australis L. and fluoroquinolone antibacterial medicine containing compound medicine for livestock and poultry |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103989730A true CN103989730A (en) | 2014-08-20 |
Family
ID=51304231
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410230436.XA Pending CN103989730A (en) | 2014-05-28 | 2014-05-28 | Acalypha australis L. and fluoroquinolone antibacterial medicine containing compound medicine for livestock and poultry |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103989730A (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106109549A (en) * | 2016-08-22 | 2016-11-16 | 广西大学 | A kind of poultry compound medicine containing Herba Euphorbiae Humifusae and norfloxacin |
| CN106138320A (en) * | 2016-08-22 | 2016-11-23 | 广西大学 | A kind of poultry compound medicine containing Fructus Rosae Laevigatae and norfloxacin |
| CN106236885A (en) * | 2016-09-21 | 2016-12-21 | 广西大学 | A kind of poultry compound medicine containing Herba Euphorbiae Humifusae, Fructus Rosae Laevigatae and norfloxacin |
| CN106265920A (en) * | 2016-09-21 | 2017-01-04 | 广西大学 | A kind of poultry compound medicine containing Radix Glycyrrhizae, Cortex Cinnamomi and norfloxacin |
| CN106309632A (en) * | 2016-09-21 | 2017-01-11 | 广西大学 | Livestock and poultry compound drug with Cortex Cinnamomi, Fructus Rosae Laevigatae and norfloxacin |
| CN106309631A (en) * | 2016-09-21 | 2017-01-11 | 广西大学 | Livestock and poultry compound drug with Radix Glycyrrhizae, Fructus Rosae Laevigatae and norfloxacin |
-
2014
- 2014-05-28 CN CN201410230436.XA patent/CN103989730A/en active Pending
Non-Patent Citations (5)
| Title |
|---|
| 于文蕴: "大力研发中兽药及中兽药饲料添加剂是我国发展兽药的重要领域 ", 《中国动物保健》 * |
| 于文蕴: "大力研发中兽药及中兽药饲料添加剂是我国发展兽药的重要领域", 《中国动物保健》 * |
| 祝凌云等: "铁苋菜属植物的研究现状 ", 《海峡药学》 * |
| 祝凌云等: "铁苋菜属植物的研究现状", 《海峡药学》 * |
| 黄迪海 等: "兽用氟喹诺酮药物长效制剂的研究与应用进展", 《山东农业科学》 * |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106109549A (en) * | 2016-08-22 | 2016-11-16 | 广西大学 | A kind of poultry compound medicine containing Herba Euphorbiae Humifusae and norfloxacin |
| CN106138320A (en) * | 2016-08-22 | 2016-11-23 | 广西大学 | A kind of poultry compound medicine containing Fructus Rosae Laevigatae and norfloxacin |
| CN106236885A (en) * | 2016-09-21 | 2016-12-21 | 广西大学 | A kind of poultry compound medicine containing Herba Euphorbiae Humifusae, Fructus Rosae Laevigatae and norfloxacin |
| CN106265920A (en) * | 2016-09-21 | 2017-01-04 | 广西大学 | A kind of poultry compound medicine containing Radix Glycyrrhizae, Cortex Cinnamomi and norfloxacin |
| CN106309632A (en) * | 2016-09-21 | 2017-01-11 | 广西大学 | Livestock and poultry compound drug with Cortex Cinnamomi, Fructus Rosae Laevigatae and norfloxacin |
| CN106309631A (en) * | 2016-09-21 | 2017-01-11 | 广西大学 | Livestock and poultry compound drug with Radix Glycyrrhizae, Fructus Rosae Laevigatae and norfloxacin |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103989728B (en) | It is a kind of to contain the livestock and poultry compound medicine containing pearl grass and beta-lactam class antimicrobial | |
| CN103690952B (en) | The compound medicine for the treatment of poultry coli-infection disease | |
| CN103989730A (en) | Acalypha australis L. and fluoroquinolone antibacterial medicine containing compound medicine for livestock and poultry | |
| CN103989725A (en) | Acalypha australis L. and amikacin containing compound medicine for livestock and poultry | |
| CN103948930A (en) | Red paeonia/beta-lactam-antibacterial-agent-containing compound medicine for livestock and fowl | |
| CN103933086A (en) | Creat/amikacin-containing compound medicine for livestock and fowl | |
| CN103989729A (en) | Acalypha australis L. and sulfamonomethoxine sodium containing compound medicine for livestock and poultry | |
| CN103989731A (en) | Acalypha australis L. and florfenicol containing compound medicine for livestock and poultry | |
| CN103989727A (en) | Acalypha australis L. and mequindox containing compound medicine for livestock and poultry | |
| CN103977088B (en) | A kind of poultry compound medicine containing Radix Paeoniae Rubra and fluoroquinolone antibacterial agent | |
| CN103948656B (en) | A kind of poultry compound medicine containing Herba Andrographis and fosfomycin | |
| CN103989726A (en) | Acalypha australis L. and fosfomycin containing compound medicine for livestock and poultry | |
| CN104306420A (en) | Balsamiferou blumea herb and sulfamonomethoxine sodium containing compound medicine for livestock and poultry | |
| CN103948691A (en) | Red paeonia/sulfamonomethoxine sodium-containing compound medicine for livestock and fowl | |
| CN103908670B (en) | A kind of compound treating poultry coli-infection disease | |
| CN103933544B (en) | A kind of poultry compound medicine containing Herba Andrographis and colistin | |
| CN103933543A (en) | Method for treating Escherichia coli infection diseases by using creat and colimycin | |
| CN104436160A (en) | Balsamiferou blumea herb and colistin containing compound medicine for livestock and poultry | |
| CN104306422A (en) | Balsamiferou Blumea herb and beta-lactam antibacterial drug containing compound medicine for livestock and poultry | |
| CN103933085B (en) | The application of Herba Andrographitis and phosphonomycin in the compound medicine for preparing treatment livestock and poultry coli-infection disease | |
| CN103933088A (en) | Method for treating Escherichia coli infection diseases by using creat and antibacterial agents | |
| CN103948657A (en) | Creat/beta-lactam-antibacterial-agent-containing compound medicine for livestock and fowl | |
| CN104162145A (en) | Acalypha australis L. and colistin-containing compound medicine for livestock and poultry | |
| CN103933087A (en) | Method for treating Escherichia coli infection diseases by using creat and amikacin | |
| CN103933109A (en) | Method for treating animal escherichia coli infected diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20140820 |
|
| RJ01 | Rejection of invention patent application after publication |